Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy launches pravastatin sodium tablets in the US
Being the first to file, Ranbaxy will enjoy 180-day exclusivity for pravastatin 80mg. According to the company, the annual sales for the heart drug are $209 million. Pravastatin
Being the first to file, Ranbaxy will enjoy 180-day exclusivity for pravastatin 80mg. According to the company, the annual sales for the heart drug are $209 million. Pravastatin
The European Commission approval of this expanded indication for Pegintron and Rebetol results in marketing authorization with unified labeling that is valid in the current EU 27 member
Byetta also showed sustained improvements in blood glucose control and progressive weight loss through three and a half years of therapy. People with type 2 diabetes are at
According to data from the study, treatment initiated within 24 hours of symptom onset provides clinically meaningful improvements, compared with treatment initiated within 24 to 48 hours. Tamiflu
The study, which was conducted over eight years, showed that two classes of lipid-lowering drugs – statins and fibrates – significantly lower the risk of developing nerve damage
The company’s quinapril hydrochloride and hydrochlorothiazide tablets are the generic equivalents of Pfizer’s Accupril and Accuretic tablets. The approval is listed on the FDA’s website, although the company
<p>Under this agreement, Oncolys has been granted an option to acquire the Asian rights for TT-033, a novel RNA interference (RNAi) based product for the treatment of hepatitis
According to 2006 IMS data, this drug product has a total market size of approximately $750 million for all indications. Under the terms of the exclusive ten-year agreement,
The company claims that Lyrica’s approval, which received a priority review, represents a breakthrough for the more than six million Americans who suffer from this debilitating condition who
SkyePharma Inc was divested by its former parent company SkyePharma plc in March 2007 and was subsequently acquired by San Diego-based Pacira Inc (formerly Blue Acquisition Corporation), which